Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730 · View on ClinicalTrials.gov ↗

Study Summary

An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.

Interventions

  • DEVICE Endovascular

Study Locations (10)

Other

  • Rigshospitalet — Copenhagen
  • Centre Hospitalier Universitaire Strasbourg — Strasbourg
  • Universitatsmedizin Frankfurt — Frankfurt
  • Regensburg University Hospital — Regensburg
  • Laiko General Hospital of Athens — Athens
  • Hospital Universitari de Bellvitge — Barcelona
  • Uppsala University — Uppsala

California

  • Cedars-Sinai Medical Center — Los Angeles

Indiana

  • Indiana University School of Medicine — Indianapolis

North Carolina

  • Duke University — Durham

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2025-06-19
Est. Completion 2038-08

Sponsor

W.L.Gore & Associates

117 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06658730

The ClinicalTrials.gov registry entry for NCT06658730 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 117 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Vascular Disease appearing as the primary indexed condition, and to 1 intervention — of which Endovascular is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06658730 reports 10 study locations spanning 4 distinct geographic areas — top geographies include Other, California, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06658730 about?

NCT06658730 is a clinical study titled "Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance". An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-ma...

What is the current status of trial NCT06658730?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2025-06-19. Estimated completion is 2038-08.

What conditions does trial NCT06658730 study?

This clinical trial studies the following conditions: Vascular Disease, Intramural Hematoma, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06658730?

The interventions under investigation include: Endovascular (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06658730?

This trial is sponsored by W.L.Gore & Associates, which has 117 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06658730 being conducted?

This trial has 10 study locations across California, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial